2005
Insulin Pump Treatment of Childhood Type 1 Diabetes
Weinzimer SA, Sikes KA, Steffen AT, Tamborlane WV. Insulin Pump Treatment of Childhood Type 1 Diabetes. Pediatric Clinics Of North America 2005, 52: 1677-1688. PMID: 16301088, DOI: 10.1016/j.pcl.2005.07.004.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionQuality of lifeLong-term microvascular complicationsEfficacy of CSIINormal blood sugar levelsType 1 diabetes mellitusInsulin pump treatmentChildhood Type 1Risk of hypoglycemiaBlood sugar levelsSubcutaneous insulin infusionNew insulin analoguesTreatment of childrenMicrovascular complicationsDiabetes mellitusPump treatmentSevere hypoglycemiaHemoglobin levelsTreatment optionsInsulin infusionClinical studiesAge of childrenInsulin analoguesType 1Weight gain
2004
Persistence of Benefits of Continuous Subcutaneous Insulin Infusion in Very Young Children With Type 1 Diabetes: A Follow-up Report
Weinzimer SA, Ahern JH, Doyle EA, Vincent MR, Dziura J, Steffen AT, Tamborlane WV. Persistence of Benefits of Continuous Subcutaneous Insulin Infusion in Very Young Children With Type 1 Diabetes: A Follow-up Report. Pediatrics 2004, 114: 1601-1605. PMID: 15574621, DOI: 10.1542/peds.2004-0092.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionType 1 diabetesMultiple daily injectionsSubcutaneous insulin infusionSevere hypoglycemiaDaily injectionsInsulin infusionRate of SHMonths of CSIIYoung childrenEpisodes of DKAOlder pediatric patientsVery Young ChildrenPersistence of benefitHypoglycemia frequencyYounger patientsGlycemic controlPediatric patientsPump treatmentClinic databaseSafety dataEmergency treatmentAge groupsType 1Diabetes
2002
Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups
Ahern JA, Boland EA, Doane R, Ahern JJ, Rose P, Vincent M, Tamborlane WV. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatric Diabetes 2002, 3: 10-15. PMID: 15016169, DOI: 10.1034/j.1399-5448.2002.30103.x.Peer-Reviewed Original ResearchDiabetes programContinuous subcutaneous insulin infusion (CSII) therapySubcutaneous insulin infusion therapyDiabetes-related adverse eventsDaily insulin dosesMean HbA1c levelPrimary efficacy outcomeSevere hypoglycemic eventsPatients 18 monthsPrimary safety measureInsulin infusion therapyYr of ageEfficacy outcomesHbA1c levelsAdverse eventsInjection therapyYounger patientsPump treatmentDiabetes controlHypoglycemic eventsInsulin dosesInfusion therapyTherapeutic alternativeClinic settingClinical data
1985
Intensive insulin therapy reduces counterregulatory hormone responses to hypoglycemia in patients with type I diabetes.
Simonson DC, Tamborlane WV, DeFronzo RA, Sherwin RS. Intensive insulin therapy reduces counterregulatory hormone responses to hypoglycemia in patients with type I diabetes. Annals Of Internal Medicine 1985, 103: 184-90. PMID: 3893253, DOI: 10.7326/0003-4819-103-2-184.Peer-Reviewed Original ResearchConceptsCounterregulatory hormone responsesPump treatmentHormone responseCounterregulatory hormone releaseInsulin pump treatmentPerception of hypoglycemiaIntensive insulin therapyIntensive insulin treatmentInsulin clamp techniqueType IBlood glucose levelsCounterregulatory hormonesGlucose counterregulationInsulin therapyHypoglycemic stimulusHypoglycemic episodesGlucagon releaseHealthy controlsInsulin treatmentHormone releaseStudy groupGlucose levelsHypoglycemic periodNormal controlsHypoglycemia
1982
Long-term improvement of metabolic control with the insulin pump does not reverse diabetic microangiopathy.
Tamborlane WV, Puklin JE, Bergman M, Verdonk C, Rudolf MC, Felig P, Genel M, Sherwin R. Long-term improvement of metabolic control with the insulin pump does not reverse diabetic microangiopathy. Diabetes Care 1982, 5 Suppl 1: 58-64. PMID: 7188047.Peer-Reviewed Original ResearchConceptsPump treatmentProliferative retinopathyMetabolic controlInsulin pumpType I diabetic patientsFirst monthInsulin pump treatmentRetinal fluorescein leakageDiabetic microvascular complicationsTotal daily doseNormal glucose metabolismLong-term improvementBackground retinopathyMicrovascular complicationsCreatinine clearanceDiabetic nephropathyRenal functionSerum creatinineDaily doseDiabetic patientsDiabetic microangiopathyHemoglobin levelsPump therapyPlasma glucoseClinical endpoints